Pain measurements and side effect profile of the novel cannabinoid ajulemic acid.

Authors: Kahlid Salim, Udo Schneider, Sumner Burstein, Ludwig Hoy, Matthias Karst
Neuropharmacology, June 2005

Preclinical findings on ajulemic acid (AJA) showed analgesic and anti-allodynic effects without psychoactive properties making it an appealing substance for the treatment of pain. A recently published randomized double-blind crossover clinical trial described the pain-reducing…

Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.

Authors: C. H. Ashton, P. B. Moore, P. Gallagher, A. H. Young
Journal of Psychopharmacology, May 2005

Bipolar affective disorder is often poorly controlled by prescribed drugs. Cannabis use is common in patients with this disorder and anecdotal reports suggest that some patients take it to alleviate symptoms of both mania and depression. We undertook a literature review of can…

Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism.

Authors: Angelo Vaccani, Paola Massi, Arianna Colombo, Tiziana Rubino, Daniela Parolaro
British Journal of Pharmacology, April 2005

We evaluated the ability of cannabidiol (CBD) to impair the migration of tumor cells stimulated by conditioned medium. CBD caused concentration-dependent inhibition of the migration of U87 glioma cells, quantified in a Boyden chamber. Since these cells express both cannabinoid…

Cardiovascular pharmacology of cannabinoids.

Authors: P. Pacher, S. Bátkai, G. Kunos
Handbook of Experimental Pharmacology, 2005

Cannabinoids and their synthetic and endogenous analogs affect a broad range of physiological functions, including cardiovascular variables, the most important component of their effect being profound hypotension. The mechanisms of the cardiovascular effects of cannabinoids in…